CAR T Cell Trial Targets Mesothelin
In an immunotherapy clinical trial, Dr. Mark O'Hara is using CAR T cells to attack mesothelin-expressing tumor cells in pancreatic cancer.
AACR Highlights: Saturday, September 7
Read the highlights of Saturday's sessions about tumor microenvironment, recurrence, and treatment resistance, at the AACR pancreatic cancer conference.
Keytruda Runner-Up for Science Breakthrough of the Year
The Lustgarten Foundation shares the story that Keytruda (pembrolizumab) is a runner-up in Science magazine's Breakthrough of the year.
New SU2C-Lustgarten Foundation Research Team Aims to Apply CAR T Cell Therapy to Pancreatic Cancer
The approach is called chimeric antigen receptor (CAR) T cell therapy, which uses specially modified immune cells to find and…
Caris Life Sciences and The Lustgarten Foundation Collaborate to Support Immunotherapy Clinical Trial for Pancreatic Cancer
Caris is providing clinical trial enrollment services to identify potential trial candidates based on biomarker expression results and facilitate communication…
Pancreatic Tumors Rely on Signals from Surrounding Cells
Now, Salk scientists have pinned down how signals from this microenvironment encourage pancreatic tumors to grow by altering their metabolism.…
